Full Press Release Details
chat #3 November 13th
is a development stage company that is creating special purpose nanomaterials
for viral therapy. The Company's novel nanoviricide class of drug candidates
are designed to specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral diseases
including H5N1 bird flu, seasonal influenza, HIV, EKC/herpes (epidemic
kerato-conjunctivitis or severe pink eye disease), hepatitis C, rabies, dengue
fever, and Ebola virus, among others.
interview contains forward-looking statements that reflect the Company's current
expectation regarding future events. Forward-looking statements involve risks
and uncertainties. Actual events could differ materially and substantially from
those projected herein and depend on a number of factors. Certain statements in
this release, and other written or oral statements made by NanoViricides, Inc.
are "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause actual results, performance, or
achievements of the company to be different from those expressed or implied
including the success of the Company's research and development efforts, the
availability of adequate financing, the successful and timely completion of
clinical studies and the uncertainties related to the regulatory process,
described in the "Management's Discussion and Analysis" section of the Company's
Form 10-KSB and other reports and filings with the Securities and Exchange
to address some of the queries I receive by email
You have been talking about discussions with various big pharmas. Why don't you
have a pharma deal done?
glacial pace of my pharma negotiations has been a major source of frustration
for me. It took me a long time to understand why these pharmas move so slowly.
They're just VERY large bureaucracies. Most all have adopted a new procedure
when evaluating "deals' with outside biotechs. This process requires extensive
analysis by outside business consultants. Following their report, there are a
number of internal hurdles that still must be bridged. Most internal people are
not interested in increasing their workload and they tend to drag their feet
when it comes to new deals, especially when these deals are related to new
technologies. Many of these lower level people have no significant stake in the
financial success of their employer. It appears to me that these relationships
may take at least one to two years to solidify. One year has just passed! The
Japanese pharmas are even more risk averse and slower to act than the Americans.
They are awaiting the test results from our collaborator in Tokyo. He himself is
awaiting hospital approval to begin the necessary studies. However, we did
report on November 10th that we
had presented at an international ophthalmology meeting. This was the first
meeting in which we had made a presentation whose attendees were all clinicians.
We had a very positive response from that presentation. Two of the previously
most interested pharmas had representatives in attendance for our talk. The
tenor of our discussions have now heated up because of that presentation.
Nothing like the fear of potentially losing a deal to spur people
What about large Foundations such as the Gates Foundation?
contacts at the highest levels of the Gates Foundation. Their focus now is on
HIV, malaria and tuberculosis. When we complete the next set of studies on HIV,
I plan to approach them. It's all about the data! I don't want to compromise my
chances of success by going in to see them too early, without a complete data
You had frequent announcements in the summer and it's quieter now.
the summer we were wrapping up a number of studies. We've embarked on another
research cycle and more data will be available over the next three to six months
from the following animal studies
the above, except f and g, once approved, have significant revenue
The website is out of date. When will you have a new site
website has been completed and is now undergoing quality review. It has a number
of features that people have asked for including a better explanation of the
nature of the technology. This is always a problem because one can never be
certain about how the technology works at the 20 nm level. That's twenty
billionths of a meter! Also, if you claim mechanism of action, the FDA can make
you prove it. That merely extends the approval process. Personally, I only care
In the past, you've spoken about moving from Connecticut to new facilities which
also can serve as manufacturing facilities.
received financial offers from two States and are awaiting a third. I hope to
make a decision by the end of the year. State money will help move us more
rapidly to my goal of revenue in the veterinary world in the next 18-30 months.
Achieving that goal is predicated upon a number of factors, not the least of
which is funding for the prototype pilot as well as the toxicology studies,
necessary for submission to both the human FDA side as well as to the Center for
Veterinary Medicine at the FDA